Literature DB >> 10571262

Co-secretion of two distinct kappa light chains by the mu-9 hybridoma.

I S Krishnan1, H J Hansen, D V Gold, D M Goldenberg, S O Leung.   

Abstract

Mu-9 is a monoclonal antibody (MAb) specific for the CSAp antigen (Ag) expressed by colorectal cancers. By using variable (V)-region-specific primers, the respective VH and VL sequences of Mu-9 were polymerase chain reaction (PCR)-amplified. However, chimeric Ab (cMu-9-1) constructed from these PCR-amplified V sequences failed to bind the CSAp Ag. Although the light chain of murine Mu-9 was not glycosylated, that of cMu-9-1 was found to be O-glycosylated, as confirmed by reducing SDS-PAGE analyses, glycoprotein blotting and O-linked specific deglycosylation studies. Removal of O-linked oligosaccharides either by enzymatic digestion or by blocking O-glycosylation with a specific inhibitor did not restore the immunoreactivity of cMu-9-1, indicating that light chain O-glycosylation was not the cause for lack of immunoreactivity. We reported earlier that screening of a Mu-9 cDNA library uncovered the presence of an additional light chain sequence that was later proven to be the authentic light chain of Mu-9. Analyses of the cDNA sequence encoding the nonimmunoreactive light chain, however, revealed no defects that would preclude the sequence from being translated and secreted by the murine hybridoma. By adapting the Mu-9 hybridoma culture to serum-free conditions, we confirmed the secretion of low levels of O-glycosylated light chain. The biological significance of the O-glycosylation as well as the cosecretion of both light chains with respect to allelic exclusion are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571262     DOI: 10.1089/hyb.1999.18.325

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  1 in total

1.  Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.

Authors:  John Bernet; Muzammil Ahmad; Jayati Mullick; Yogesh Panse; Akhilesh K Singh; Pradeep B Parab; Arvind Sahu
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 4.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.